Equillium, Inc.

Equillium, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapeutics for severe autoimmune and inflammatory disorders with high unmet medical needs. Founded in 2017, the company is headquartered in La Jolla, California.

The company's pipeline focuses on immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its lead product candidate, EQ504, is a potent and selective aryl hydrocarbon receptor (AhR) modulator, currently being advanced into clinical development for severe inflammatory diseases such as ulcerative colitis and pouchitis. Another key candidate, EQ302, is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, intended for gastrointestinal and skin diseases. Historically, Equillium also developed itolizumab (EQ001), a monoclonal antibody for conditions like acute Graft-Versus-Host Disease, lupus nephritis, and asthma, which was licensed from Biocon Limited.

Under the leadership of CEO Bruce Steel, Equillium recently announced a $35 million financing round with RA Capital Management in March 2026, aimed at accelerating the clinical advancement of EQ504 and extending the company's cash runway into 2029. The company is strategically prioritizing the development of EQ504. Equillium operates as a publicly traded entity, listed on NASDAQ under the ticker symbol EQ.